Back

TRAIL agonists rescue mice from radiation-induced lung injury

Strandberg, J.; Louie, A. D.; Lee, S.; Hahn, M.; Srinivasan, P.; George, A.; De La Cruz, A.; Zhang, L.; Borrero, L. H.; Huntington, K. E.; De La Cruz, P.; Seyhan, A. A.; Koffer, P. P.; Wazer, D. E.; DiPetrillo, T. A.; Azzoli, C. G.; Rounds, S. I.; Graff, S. L.; Abbas, A. E.; Zhou, L.; El-Deiry, W. S.

2023-06-13 pathology
10.1101/2023.06.12.544681 bioRxiv
Show abstract

Cancer therapy is often limited by toxicity from pneumonitis. This often-lethal side effect is known to be impacted by innate immunity, and in particular the pathways regulated by the TRAIL death receptor DR5. We investigated whether DR5 agonists could rescue mice from the lethal effects of radiation. We found that two different agonists, parenteral PEGylated trimeric-TRAIL (TLY012) and oral TRAIL-Inducing Compound #10 (TIC10/ONC201), could achieve this goal. Both compounds could completely protect mice from lethality by reducing pneumonitis, alveolar-wall thickness, and oxygen desaturation. At the molecular level, this protection appeared to be due to the inhibition of CCl22, a macrophage-derived chemokine previously associated with radiation pneumonitis and pulmonary fibrosis. The discovery that short-term treatment with TRAIL pathway agonists effectively rescues animals from high doses of radiation exposure has important translational implications. One Sentence SummaryPrevention of lethality, pneumonitis, lung fibrosis and skin dermatitis post-{psi}-irradiation by short- term treatment with innate immune TRAIL pathway agonists

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 8%
11.8%
Similar papers in this journal
2
Scientific Reports
○ 3612 papers in training set
Top 5%
9.6%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 22%
7.2%
Similar papers in this journal
4
PLOS ONE
● 5266 papers in training set
Top 25%
6.2%
Similar papers in this journal
5
International Journal of Radiation Oncology*Biology*Physics
○ 25 papers in training set
Top 0.1%
5.5%
Similar papers in this journal
6
Radiotherapy and Oncology
○ 19 papers in training set
Top 0.1%
5.4%
7
Cancers
○ 213 papers in training set
Top 1%
4.3%
50% of probability mass above
8
Molecular Cancer Research
● 49 papers in training set
Top 0.2%
4.0%
9
Science Advances
● 1243 papers in training set
Top 8%
4.0%
10
Cancer Research Communications
● 51 papers in training set
Top 0.4%
2.8%
11
Cancer Letters
○ 35 papers in training set
Top 0.3%
2.6%
12
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.3%
2.4%
13
Clinical Cancer Research
● 64 papers in training set
Top 0.9%
2.4%
14
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 24%
2.1%
15
Theranostics
● 37 papers in training set
Top 0.4%
1.7%
16
Frontiers in Oncology
○ 103 papers in training set
Top 2%
1.5%
17
iScience
○ 1154 papers in training set
Top 21%
1.5%
18
Biochemistry and Biophysics Reports
○ 30 papers in training set
Top 0.8%
1.1%
19
BMC Cancer
○ 67 papers in training set
Top 2%
1.1%
20
JNCI Cancer Spectrum
◐ 10 papers in training set
Top 0.2%
1.1%
21
npj Precision Oncology
○ 53 papers in training set
Top 1%
1.0%
22
Cancer Research
● 130 papers in training set
Top 3%
1.0%
23
International Journal of Cancer
○ 49 papers in training set
Top 1.0%
1.0%
24
Neuro-Oncology
◐ 36 papers in training set
Top 0.5%
0.9%
25
Cell Death & Disease
147 papers in training set
Top 3%
0.9%
26
Gut Microbes
○ 78 papers in training set
Top 1%
0.8%
27
Clinical and Translational Radiation Oncology
○ 10 papers in training set
Top 0.2%
0.6%
28
The American Journal of Pathology
○ 32 papers in training set
Top 1%
0.6%
29
Cell Reports
○ 1498 papers in training set
Top 29%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.